University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Malar J. 2021 Apr 21;20(1):196. doi: 10.1186/s12936-021-03689-z.
Interferon (IFN)- λ4, a type III IFN, production is controlled by a dinucleotide frameshift variant (rs368234815-dG/TT) within the first exon of the IFNL4 gene. Carriers of the IFNL4-dG allele but not the IFNL4-TT allele are able to produce the IFN-λ4 protein. Patients with hepatitis C virus that do not produce the IFN-λ4 protein have higher rates of viral clearance suggesting a potential inhibitory role of IFN-λ4 in liver-tropic infections.
In this study, it was investigated whether children infected with Plasmodium falciparum, which has a well-characterized liver stage infection, would be more susceptible to clinical malaria relative to their IFNL4-rs368234815 allele. A cohort of 122 children from a malaria holoendemic region of Kenya was analysed. Episodes of clinical malaria and upper respiratory tract infections (URTIs) were determined using information collected from birth to 2 years of age. The dinucleotide frameshift variant IFNL4-rs368234815-dG/TT was genotyped using a TaqMan assay.
In this cohort, 33% of the study participants had the dG/dG genotype, 45% had the dG/TT genotype, and 22% had TT/TT genotype. The number and time to first episode of clinical malaria and URTIs with respect to the IFNL4-rs368234815 allele was evaluated. It was found that children that carried the IFNL4-rs368234815-dG allele had an increased number of clinical malaria episodes. In addition, there was a significant association between earlier age of first malaria infection with carriers of the IFNL4-dG allele (p-value: 0.021).
The results suggest that the ability to produce IFN-λ4 negatively affects host immune protection against P. falciparum malaria in Kenyan children.
干扰素(IFN)-λ4 是一种 III 型干扰素,其在 IFNL4 基因的第一个外显子内由一个二核苷酸移码变异(rs368234815-dG/TT)控制。IFNL4-dG 等位基因的携带者但不是 IFNL4-TT 等位基因的携带者能够产生 IFN-λ4 蛋白。未产生 IFN-λ4 蛋白的丙型肝炎病毒患者具有更高的病毒清除率,这表明 IFN-λ4 在肝嗜性感染中可能具有潜在的抑制作用。
在这项研究中,研究了感染疟原虫的儿童是否相对于其 IFNL4-rs368234815 等位基因更容易发生临床疟疾。对肯尼亚一个疟疾全流行地区的 122 名儿童进行了分析。通过收集出生到 2 岁的信息,确定了临床疟疾和上呼吸道感染(URTI)的发作。使用 TaqMan 测定法对二核苷酸移码变异 IFNL4-rs368234815-dG/TT 进行了基因分型。
在该队列中,33%的研究参与者具有 dG/dG 基因型,45%具有 dG/TT 基因型,22%具有 TT/TT 基因型。评估了 IFNL4-rs368234815 等位基因与临床疟疾和 URTI 的首次发作次数和时间。结果发现,携带 IFNL4-rs368234815-dG 等位基因的儿童临床疟疾发作次数更多。此外,携带 IFNL4-dG 等位基因的儿童首次疟疾感染年龄较早与该等位基因之间存在显著关联(p 值:0.021)。
结果表明,产生 IFN-λ4 的能力对肯尼亚儿童宿主对疟原虫疟疾的免疫保护产生负面影响。